Sonoma Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	2.4	5.37	3.13	3.82	7.4
Cash & Short-Term Investments	2.4	5.37	3.13	3.82	7.4
Cash Growth	-55.36%	71.80%	-18.12%	-48.35%	75.26%
Accounts Receivable	2.53	2.23	2.9	2.57	2.41
Inventory	3.65	2.92	2.72	2.86	2.66
Other Current Assets	3.52	2.13	3.8	4.55	3.96
Total Current Assets	12.1	12.65	12.55	13.8	16.43
Net Property, Plant & Equipment	0.91	0.31	0.65	0.91	0.88
Other Long-Term Assets	0.95	0.74	1.54	1.53	1.54
Total Assets	13.96	13.69	14.74	16.23	18.85
Accounts Payable	1.92	0.95	0.61	0.84	1.64
Accrued Expenses	2.25	2.22	2.11	2.03	1.84
Short-Term Debt	0.22	0.22	0.32	0.43	0.69
Current Portion of Long-Term Debt	-	-	-	-	0.12
Current Portion of Leases	0.15	0.06	0.2	0.26	0.25
Unearned Revenue	0.28	0.64	0.48	0.16	1.28
Total Current Liabilities	4.83	4.1	3.72	3.72	5.82
Long-Term Leases	0.47	0.03	0.09	0.16	0.31
Other Long-Term Liabilities	5.56	5.16	4.8	4.38	4.02
Total Long-Term Liabilities	6.03	5.19	4.88	4.54	4.33
Total Liabilities	10.87	9.28	8.6	8.25	10.15
Common Stock	-	-	-	0.01	0
Additional Paid-in Capital	207.32	206.59	203.21	200.9	197.37
Accumulated Other Comprehensive Income	-3.24	-4.38	-2.72	-3.42	-4.31
Retained Earnings	-200.98	-197.81	-194.35	-189.51	-184.36
Shareholders' Equity	3.1	4.41	6.14	7.98	8.7
Total Liabilities & Equity	13.96	13.69	14.74	16.23	18.85
Total Debt	0.84	0.31	0.61	0.85	1.37
Net Cash (Debt)	1.56	5.07	2.52	2.97	6.03
Net Cash Growth	-69.28%	101.15%	-15.18%	-50.72%	290.23%
Net Cash Per Share	0.93	4.08	5.54	17.51	45.45
Book Value	3.1	4.41	6.14	7.98	8.7
Book Value Per Share	1.84	3.55	13.49	47.01	65.56
Tangible Book Value	3.1	4.41	6.14	7.98	8.7
Tangible Book Value Per Share	1.84	3.55	13.49	47.01	65.56

SEC Filings: 10-K · 10-Q